Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models

European Journal of Pharmacology

Volumn 802, Issue , 2017, Pages 60-68

  Nakamura, Masaki ^a   Takeuchi, Takashi ^a   Kawahara, Tetsushi ^a   Hirose, Jiro ^a   Nakayama, Kazuyuki ^a   Hosaka, Yoshitaka ^a   Furusako, Shoji ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Bikunin; Inter inhibitor; Lipopolysaccharide; Ulinastatin; Urinary trypsin inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 11A; CD14 ANTIGEN; CD14 HUMAN CHIMERIC ANTIBODY MODIFIED SECOND DOMAIN BIKUNIN FUSION PROTEIN; CHROMOGENIC SUBSTRATE; HEPARIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALPHA GLOBULIN; ALPHA-1-MICROGLOBULIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSOCIATION RATE CONSTANT; BACTERIAL COUNT; BLEEDING TIME; BLOOD LEVEL; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; ENDOTOXEMIA; ENZYME PURIFICATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLATELET-RICH PLASMA CELL; SEPSIS; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTE COUNT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN DOMAIN; RABBITS AND HARES; SURVIVAL ANALYSIS;

ALPHA-GLOBULINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTIGENS, CD14; BLEEDING TIME; DISEASE MODELS, ANIMAL; E-SELECTIN; ENDOTOXEMIA; FACTOR XIA; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; PROTEIN DOMAINS; RABBITS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS;

EID: 85013915665     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.02.045     Document Type: Article

References (37)

1. Angstwurm, M.W., Dempfle, C.E., Spannagl, M., New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with acute physiology and chronic health evaluation II and logistic organ dysfunction scores. Crit. Care Med. 34 (2006), 314–320 〈https://www.ncbi.nlm.nih.gov/pubmed/16424708〉.
2. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29 (2001), 1303–1310 〈https://www.ncbi.nlm.nih.gov/pubmed/11445675〉.
3. Annane, D., Bellissant, E., Cavaillon, J.M., Septic shock. Lancet 365 (2005), 63–78 〈https://www.ncbi.nlm.nih.gov/pubmed/15639681〉.
4. Antal-Szalmás, P., Evaluation of CD14 in host defence. Eur. J. Clin. Investig. 30 (2000), 167–179 〈https://www.ncbi.nlm.nih.gov/pubmed/10651843〉.
5. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., Fisher, C.J. Jr., Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001), 699–709 〈https://www.ncbi.nlm.nih.gov/pubmed/11236773〉.
6. Buras, J.A., Holzmann, B., Sitkovsky, M., Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4 (2005), 854–865 〈https://www.ncbi.nlm.nih.gov/pubmed/16224456〉.
7. Cruz, D.N., Perazella, M.A., Bellomo, R., de Cal, M., Polanco, N., Corradi, V., Lentini, P., Nalesso, F., Ueno, T., Ranieri, V.M., Ronco, C., Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit. Care, 11, 2007, R47 〈https://www.ncbi.nlm.nih.gov/pubmed/17448226〉.
8. Eichacker, P.Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S.M., Gerstenberger, E.P., Fitz, Y., Danner, R.L., Natanson, C., Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166 (2002), 1197–1205 〈https://www.ncbi.nlm.nih.gov/pubmed/12403688〉.
9. Engelmann, B., Massberg, S., Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13 (2013), 34–45 〈https://www.ncbi.nlm.nih.gov/pubmed/23222502〉.
10. Esmon, C.T., Why do animal models (sometimes) fail to mimic human sepsis? Crit. Care Med. 32:5 Suppl (2004), S219–S222 〈https://www.ncbi.nlm.nih.gov/pubmed/15118521〉.
11. Ferrero, E., Jiao, D., Tsuberi, B.Z., Tesio, L., Rong, G.W., Haziot, A., Goyert, S.M., Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA 90 (1993), 2380–2384 〈https://www.ncbi.nlm.nih.gov/pubmed/7681594〉.
12. Frevert, C.W., Matute-Bello, G., Skerrett, S.J., Goodman, R.B., Kajikawa, O., Sittipunt, C., Martin, T.R., Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J. Immunol. 164 (2000), 5439–5445 〈https://www.ncbi.nlm.nih.gov/pubmed/10799910〉.
13. Gailani, D., Renne, T., The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. J. Thromb. Haemost. 5 (2007), 1106–1112 〈https://www.ncbi.nlm.nih.gov/pubmed/17388803〉.
14. Haziot, A., Ferrero, E., Köntgen, F., Hijiya, N., Yamamoto, S., Silver, J., Stewart, C.L., Goyert, S.M., Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4 (1996), 407–414 〈https://www.ncbi.nlm.nih.gov/pubmed/8612135〉.
15. He, R., Chen, D., He, S., Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb. Res. 129 (2012), 541–550 〈https://www.ncbi.nlm.nih.gov/pubmed/22197449〉.
16. Hirose, J., Ozawa, T., Miura, T., Isaji, M., Nagao, Y., Yamashiro, K., Nii, A., Kato, K., Uemura, A., Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol. Pharm. Bull. 21 (1998), 651–656 〈https://www.ncbi.nlm.nih.gov/pubmed/9703243〉.
17. Hornef, M.W., Wick, M.J., Rhen, M., Normark, S., Bacterial strategies for overcoming host innate and adaptive immune responses. Nat. Immunol. 3 (2002), 1033–1040 〈https://www.ncbi.nlm.nih.gov/pubmed/12407412〉.
18. Huber-Lang, M., Barratt-Due, A., Pischke, S.E., Sandanger, Ø., Nilsson, P.H., Nunn, M.A., Denk, S., Gaus, W., Espevik, T., Mollnes, T.E., Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J. Immunol. 192 (2014), 5324–5331 〈https://www.ncbi.nlm.nih.gov/pubmed/24790148〉.
19. Ishii, H., Takada, K., Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel. Toxicol. Appl. Pharmacol. 184 (2002), 88–97 〈https://www.ncbi.nlm.nih.gov/pubmed/12408953〉.
20. Le Roy, D., Di Padova, F., Adachi, Y., Glauser, M.P., Calandra, T., Heumann, D., Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. J. Immunol. 167 (2001), 2759–2765 〈https://www.ncbi.nlm.nih.gov/pubmed/11509620〉.
21. Leturcq, D.J., Moriarty, A.M., Talbott, G., Winn, R.K., Martin, T.R., Ulevitch, R.J., Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Investig. 98 (1996), 1533–1538 〈https://www.ncbi.nlm.nih.gov/pubmed/8833900〉.
22. Levi, M., Ten Cate, H., Disseminated intravascular coagulation. N. Engl. J. Med. 341 (1999), 586–592 〈https://www.ncbi.nlm.nih.gov/pubmed/10451465〉.
23. Mann, K.G., Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82 (1999), 165–174 〈https://www.ncbi.nlm.nih.gov/pubmed/10605701〉.
24. Martin, G.S., Mannino, D.M., Eaton, S., Moss, M., The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348 (2003), 1546–1554 〈https://www.ncbi.nlm.nih.gov/pubmed/12700374〉.
25. Nakamura, M., Takeuchi, T., Maeda, Y., Hosaka, Y., Furusako, S., Characterization of a novel variant of the second domain of bikunin with increased leukocyte elastase inhibitory activity. J. Biophys. Chem. 3 (2012), 132–141, 10.4236/jbpc.2012.32015.
26. Opal, S.M., Glück, T., Endotoxin as a drug target. Crit. Care Med. 31:1 Suppl (2003), S57–S64 〈https://www.ncbi.nlm.nih.gov/pubmed/12544978〉.
27. Page, A.V., Liles, W.C., Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 4 (2013), 507–516 〈https://www.ncbi.nlm.nih.gov/pubmed/23669075〉.
28. Płóciennikowska, A., Hromada-Judycka, A., Borzęcka, K., Kwiatkowska, K., Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 72 (2015), 557–581 〈https://www.ncbi.nlm.nih.gov/pubmed/25332099〉.
29. Pugia, M.J., Lott, J.A., Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin. Chem. Lab. Med. 43 (2005), 1–16 〈https://www.ncbi.nlm.nih.gov/pubmed/15653436〉.
30. Redl, H., Bahrami, S., Schlag, G., Traber, D.L., Clinical detection of LPS and animal models of endotoxemia. Immunobiology 187 (1993), 330–345 〈https://www.ncbi.nlm.nih.gov/pubmed/8330902〉.
31. Russell, J.A., Management of sepsis. N. Engl. J. Med. 355 (2006), 1699–1713 〈https://www.ncbi.nlm.nih.gov/pubmed/17050894〉.
32. Schimke, J., Mathison, J., Morgiewicz, J., Ulevitch, R.J., Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA 95 (1998), 13875–13880 〈https://www.ncbi.nlm.nih.gov/pubmed/9811894〉.
33. Tucker, E.I., Gailani, D., Hurst, S., Cheng, Q., Hanson, S.R., Gruber, A., Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J. Infect. Dis. 198 (2008), 271–274 〈https://www.ncbi.nlm.nih.gov/pubmed/18491973〉.
34. Vincent, J.L., Ramesh, M.K., Ernest, D., LaRosa, S.P., Pachl, J., Aikawa, N., Hoste, E., Levy, H., Hirman, J., Levi, M., Daga, M., Kutsogiannis, D.J., Crowther, M., Bernard, G.R., Devriendt, J., Puigserver, J.V., Blanzaco, D.U., Esmon, C.T., Parrillo, J.E., Guzzi, L., Henderson, S.J., Pothirat, C., Mehta, P., Fareed, J., Talwar, D., Tsuruta, K., Gorelick, K.J., Osawa, Y., Kaul, I., A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit. Care Med. 41 (2013), 2069–2079 〈https://www.ncbi.nlm.nih.gov/pubmed/23979365〉.
35. Wiedermann, C.J., Hoffmann, J.N., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Keinecke, H.O., Warren, B.L., Opal, S.M., KyberSept investigators: high-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit. Care Med. 34 (2006), 285–292 〈https://www.ncbi.nlm.nih.gov/pubmed/16424704〉.
36. Wielders, S.J., Béguin, S., Hemker, H.C., Lindhout, T., Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1138–1142 〈https://www.ncbi.nlm.nih.gov/pubmed/15072993〉.
37. Zeerleder, S., Hack, C.E., Wuillemin, W.A., Disseminated intravascular coagulation in sepsis. Chest 128 (2005), 2864–2875 〈https://www.ncbi.nlm.nih.gov/pubmed/16236964〉.